Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial
E. Fontanilles (Hospitalet de Llobregat, Spain), C. Vancheri (Catania, Italy), M. Wijsenbeek (Rotterdam, Netherlands), K. Antoniou (Heraklion, Greece), P. Rivera (Maanchester, United Kingdom), F. Bonella (Essen, Germany), E. Renzoni (London, United Kingdom), A. Anne-Marie (London, United Kingdom), V. Vicens-Zygmunt (Hospitalet de Llobregat, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), J. Dorca (Hospitalet de Llobregat, Spain), J. Palma (Hospitalet de Llobregat, Spain), A. Bachs (Hospitalet de Llobregat, Spain), V. Avilés (Barcelona, Spain), C. Tebé (Hospitalet de Llobregat, Spain), J. Shull (Hospitalet de Llobregat, Spain), M. Molina Molina (Hospitalet de Llobregat, Spain)
Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Fontanilles (Hospitalet de Llobregat, Spain), C. Vancheri (Catania, Italy), M. Wijsenbeek (Rotterdam, Netherlands), K. Antoniou (Heraklion, Greece), P. Rivera (Maanchester, United Kingdom), F. Bonella (Essen, Germany), E. Renzoni (London, United Kingdom), A. Anne-Marie (London, United Kingdom), V. Vicens-Zygmunt (Hospitalet de Llobregat, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), J. Dorca (Hospitalet de Llobregat, Spain), J. Palma (Hospitalet de Llobregat, Spain), A. Bachs (Hospitalet de Llobregat, Spain), V. Avilés (Barcelona, Spain), C. Tebé (Hospitalet de Llobregat, Spain), J. Shull (Hospitalet de Llobregat, Spain), M. Molina Molina (Hospitalet de Llobregat, Spain). Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial. 3712
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Supplementation with omega-3 fatty acids and atopy symptoms in infants: a randomized controlled trial Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Omega-3 polyunsaturated fatty acids and FADS genotype: is personalised prevention of asthma on the horizon? Source: Eur Respir J, 58 (3) 2101386; 10.1183/13993003.01386-2021 Year: 2021
Oral polyunsaturated fatty acid supplementation as adjuvant therapy for asthmatic children Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012
Intake of n -3 polyunsaturated fatty acids in childhood, FADS genotype and incident asthma Source: Eur Respir J, 58 (3) 2003633; 10.1183/13993003.03633-2020 Year: 2021
Late Breaking Abstract: Prenatal n-3, n-6, and trans fatty acids and the risk of eosinophilia and allergic sensitization in children at age 3 years Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
Dietary supplementation over one year with fatty acids reduces inflammatory markers and produces clinical improvement in adults with cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007
Inhalations of Tranexamic Acid for hemoptysis: A randomized controlled trial Source: International Congress 2018 – Studies on the mechanisms underlying airway disease Year: 2018
Effectiveness of omega-3 polyunsaturated fatty acids in combination with acetylsalicylic acid in patients with COPD, complicated by cor pulmonale and the syndrome of blood hypercoagulation Source: Eur Respir J 2004; 24: Suppl. 48, 59s Year: 2004
The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Food and fatty acid intake and atopic disease in adults Source: Eur Respir J 2004; 23: 575-582 Year: 2004
LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Effects of long-term supplementation of branched-chain amino acids on muscle metabolism in COPD patients Source: Eur Respir J 2006; 28: Suppl. 50, 638s Year: 2006
Effects of n-3 polyunsaturated fatty acids on inflammatory markers in chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 39s Year: 2006
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Glucocorticoids correct fatty acids composition in asthma patients. Composition of fatty acids in high density lipoproteins in bronchitis patients Source: Eur Respir J 2007; 30: Suppl. 51, 145s Year: 2007
Effect of omega-3 and phosphoethanolamine in patients with asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Late-breaking abstract: Cycloxygenase- and lypoxigenase-dependent generation of omega-3 electrophilic fatty acid-derivatives with anti-inflammatory properties Source: Annual Congress 2011 - Lung cell biology Year: 2011
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2008; 31: 1024-1029 Year: 2008
Polyunsaturated fatty acids, lactobacillus bifidus, vitamin A and D in the treatment of IgA immunodeficiency in children with frequent respiratory infections Source: Eur Respir J 2004; 24: Suppl. 48, 357s Year: 2004